APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.03-0.1μg/ml |
Not tested in other applications.
Calculated MW
Positive Control
The peptide used to generate this antibody is available for purchase (GTX89682-PEP).
Product Note
This antibody is expected to recognise both the human SART1(800) and SART1(259) proteins.
Predict Reactivity
Mouse, Rat, Bovine(>80% identity)
PROPERTIES
Form
Liquid
Buffer
TBS, 0.5% BSA
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Peptide with sequence GSSKKHRGEKEAA-C, from the N Terminus of the protein sequence according to NP_005137.1.
Purification
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP , Ara1 , HAF , HOMS1 , SART1259 , SNRNP110 , Snu66
Cellular Localization
Nucleus
Background
This gene encodes two proteins, the SART1(800) protein expressed in the nucleus of the majority of proliferating cells, and the SART1(259) protein expressed in the cytosol of epithelial cancers. The SART1(259) protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1(259) protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1(259) antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1(259) protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway. [provided by RefSeq, Jul 2008]
Database
Research Area
DATA IMAGES
|
GTX89682 WB Image
WB analysis of HeLa lysate using GTX89682 SART1 antibody, N-term.
Dilution : 0.03μg/ml
Loading : 35μg protein in RIPA buffer
|
REFERENCE
There are currently no references for SART1 antibody, N-term (GTX89682). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for SART1 antibody, N-term (GTX89682). Be the first to share your experience with this product.
